Innovation in hemophilia drug development and cost-efficiency tools
As treatment for hemophilia evolves, data proves a good specialty pharmacy partner can help minimize waste and drive efficient practices.
Read MoreNew Tests and Therapies Enable Personalized Cancer Treatment
Oncology is one of the most complex areas of medical care. Evernorth’s cancer consult service pairs subspecialists from leading cancer centers with community oncologists, improving access to the best ...
Read MoreUnderstanding Hemophilia
Breaking down the challenges, therapies and costs associated with hemophilia.
Read MoreHelping plans and patients get life-changing gene therapies
Gene therapies offer hope where none existed before, but health plans and employers need the right strategy to make these cutting-edge medications affordable and available.
Read MoreGene therapies, today and tomorrow
By supporting and encouraging evidence-based access to gene therapy, payers and other segments of U.S. society will be positioned to benefit from future advancements and biopharmaceutical breakthrough...
Read MoreHow to have a data-driven discussion on gene and cellular therapies
As the number of approved gene and cellular therapies grows, you can start preparing your organization now by taking the right next steps.
Read MoreWhat to look for in the upcoming gene therapy pipeline
As the gene therapy landscape continues to evolve, plan sponsors should familiarize themselves with the tools and strategies necessary to navigate the future of these game-changing treatments.
Read MoreUnderstanding gene modification and cellular therapies
Gene modification and cellular therapies are unique, potentially curative treatments that leverage gene-altering technology
Read MoreGene therapies 101
We answer our clients’ burning questions about gene therapies, including how they work, whether or not they’re safe, and if we’ll see more in the future.
Read MoreThe future of gene therapy
Recent research suggests that the number of gene therapies on the market is likely to increase to over 60 by 2030. As rapid advancements in the field continue, here is what plan sponsors can expect to...
Read More